Viewing Study NCT07316361


Ignite Creation Date: 2026-03-26 @ 3:14 PM
Ignite Modification Date: 2026-03-31 @ 4:51 AM
Study NCT ID: NCT07316361
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2026-01-07
First Post: 2025-12-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Sponsor: Biogenea Pharmaceuticals Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module